abt-806
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01255657)
Timeline
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- abt-806
- abt-806
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02213289 | Phase 2 | Jan 1, 2015 | AbbVie, University of Chicago |
| NCT01406119 | Phase 1 | Oct 1, 2011 | AbbVie |
| NCT01472003 | Phase 1 | Oct 1, 2011 | AbbVie |
| NCT01255657 | Phase 1 | Nov 1, 2010 | AbbVie |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 4 | 3 | 2 | 2010 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1